Friday 6 November 2026 Export IMVT’s income statement to Excel — free account

Immunovant, Inc.

IMVT Healthcare Biotechnology

EPS: −5.63%
Free cash flow: −5.96%

Quarter to June 2026, against a year earlier

Insider buying

30.53 2.14 +7.54%

Follow IMVT

Alert me

Market cap: $5.9B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Valuation Filings

Immunovant, Inc. 10-Q filed Feb 6, 2025

Fiscal Q3 2025 · Period ended Dec 31, 2024 · Filed Feb 6, 2025 · accepted 6:45 AM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov